Detalhe da pesquisa
1.
Genetic variants in C5 and poor response to eculizumab.
N Engl J Med
; 370(7): 632-9, 2014 Feb 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-24521109
2.
Efficacy and safety of dimethyl fumarate in treatment-naïve Japanese patients with multiple sclerosis: Interim analysis of the randomized placebo-controlled study.
Mult Scler J Exp Transl Clin
; 5(2): 2055217319852727, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31218077
3.
72-Week Safety and Tolerability of Dimethyl Fumarate in Japanese Patients with Relapsing-remitting Multiple Sclerosis: Analysis of the Randomised, Double Blind, Placebo-Controlled, Phase III APEX Study and its Open-Label Extension.
Adv Ther
; 35(10): 1598-1611, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30206820
4.
The burden of multiple sclerosis in Japan.
J Med Econ
; 20(12): 1290-1298, 2017 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-28849983
5.
Safety and Effectiveness of Natalizumab: First Report of Interim Results of Post-Marketing Surveillance in Japan.
Neurol Ther
; 6(2): 197-211, 2017 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-29119538